Share

July 19, 2016; 87 (3) Article

Population-based risks for cancer in patients with ALS

Summer B. Gibson, Diana Abbott, James M. Farnham, Khanh K. Thai, Hailey McLean, Karla P. Figueroa, Mark B. Bromberg, Stefan M. Pulst, Lisa Cannon-Albright
First published May 11, 2016, DOI: https://doi.org/10.1212/WNL.0000000000002757
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
284

Share

Article Information

vol. 87 no. 3 289-294
DOI: 
https://doi.org/10.1212/WNL.0000000000002757
PubMed: 
27170569
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received August 27, 2015
  • Accepted in final form March 23, 2016
  • First Published May 11, 2016.

Article Versions

Copyright & Usage: 
© 2016 American Academy of Neurology

Author Disclosures

    1. Summer B. Gibson, MD,
    2. Diana Abbott, PhD,
    3. James M. Farnham, MS,
    4. Khanh K. Thai, MS,
    5. Hailey McLean,
    6. Karla P. Figueroa, MS,
    7. Mark B. Bromberg, MD, PhD,
    8. Stefan M. Pulst, MD, Dr-Med and
    9. Lisa Cannon-Albright, PhD
  1. Summer B. Gibson, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. (1) Skin Biopsy for the Evaluation of Peripheral Nerve Disease. UpToDate. Sept 2013.

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. (1) Ogden Surgical-Medical Society 2014 annual meeting

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NCATS, TL1TR001066, Trainee, 09/03/2014 - 06/30/2016 Stock/Stock Options, Medical Equipment & Materials: (1) Recursion Pharmaceuticals, 2013-current

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Diana Abbott, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. James M. Farnham, MS,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Khanh K. Thai, MS,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Hailey McLean,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Karla P. Figueroa, MS,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Mark B. Bromberg, MD, PhD,
    8. Scientific Advisory Boards:

    1. Accordant Health Care (1995-present) Baxter Bioscience (2011-present)

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Funds for travel and and speaker honoraria: Walgreens Infusion (2009-present) Grifols Biotherapeutics (2009-present) Baxter Bioscience (2011-present)

    Editorial Boards:

    1. Muscle & Nerve, Assistant Editor (1996-1999; 2005-2009) Clinical Neurophysiology, Assistant Editor (2008-2014) J Clinical Neuromuscular Diseases, Assistant Editor (1998-present)

    Patents:

    1. NONE

    Publishing Royalties:

    1. Handbook of Peripheral Neuropathy, Taylor & Francis, 2005 Quality of Life Measurement in Neurodegenerative and Related Conditions, Cambridge, 2010 UpToDate, 2008 to present Motor Neuron Disease in Adults, 2014

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. Walgreens Infusion (2009-present) Grifols Biotherapeutics (2009-present) Baxter Bioscience (2011-present) Genzyme (2015-present)

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Stefan M. Pulst, MD, Dr-Med and
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. Nucleic acids encoding ataxin-2 binding proteins; Nucleic acid encoding Schwannomin-binding-proteins and products related thereto; Transgenic mouse expressing a polynucleotide encoding a human ataxin-2 polypeptide; Methods of detecting spinocerebellar ataxia-2 nucleic acids; Nucleic acid encoding spinocerebellar ataxia-2 and products related thereto; Shwannomin-binding-proteins; Compositions and methods for spinocerebellar ataxia

    Publishing Royalties:

    1. The Ataxias (Churchill Livingston, 2007), Genetics in Neurology (ANN Press, 2005), Genetics of Movement Disorders (Academic Press, 2003), Neurogenetics (Oxford University Press, 2000), Molecular Genetic Testing in Neurology, 2nd - 5th (AAN Press, 1996)

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Ataxion Therapeutics

    Speakers' Bureaus:

    1. Athena Diagnostics, Inc.

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) 2008-2013 National Institutes of Health (RO1NS33123): Spinocerebellar ataxia type 2: gene and gene product. 7/1/08-6/30/2013. (Principal Investigator). (2) 2010-2012 National Institutes of Health (RC1NS068897): CLINICAL RESEARCH CONSORTIUM FOR SPINOCEREBELLAR ATAXIAS, 9/1/09-8/31/12 (Principal Investigator of genomics core and site PI). (3) 2010-2013 National Institutes of Health (RC4NS073009): Drug discovery for Spinocerebellar ataxia type 2 (SCA2). 9/1/10-8/31/2013 (Principle Investigator, Co-PI, D. Scoles). (4) 2013-2015 National Institutes of Health (R21NS079852): Identification of a mutation causing Purkinje cell degeneration in the rat. 03/01/13 to 02/28/15.(Principle Investigator) (5) 2013-2015 National Institutes of Health (R21NS081182): Antisense oligonucleotides for the treatment of spinocerebellar ataxia type 2. 07/01/13 to 06/30/15 (Co-PI with D. Scoles)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National Ataxia foundation (mentor for fellowship award)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License fee payments, Technology or Inventions:

    1. Cedars-Sinai Medical Center

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. Hall & Evans, LLC (Denver, CO) Expert Testimony 2013

  9. Lisa Cannon-Albright, PhD
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Active Grants 5P30CA042014-24 (Beckerle) 5/9/97-4/30/20 1.8 calendar National Institutes of Health $950,030 Title: Cancer Center Support Grant Goals: The purpose of this project is to support the research infrastructure of the Cancer Center. It promotes scientific excellence through coordinated, broad-based interdisciplinary programs and support of state-of-the-art shared research resources. Role: Staff Investigator R01HD061821 (Cannon-Albright/Norton) 8/15/09-6/30/16 1.8 calendar National Institutes of Health $2,348,381 Title: Identification of genes predisposition to Pelvic Floor Disorders Goals: The purpose of this project is to create a population-based resource of surgically treated pelvic organ prolapse cases, pursue established an new methods to identify and localize predisposition genes affecting pelvic organ prolapse, and begin a detailed search for the chromosome 9 gene we have localized. Role: Principal Investigator R01CA164138 (Tavtigian/Cannon-Albright) 8/1/12-5/30/17 1.8 calendar National Institutes of Health $1,956,756 Title: Massively Parallel Sequencing for Familial Colon Cancer Genes Goals: The purpose of this project is to identify and characterize new colon cancer susceptibility genes. To search for high-risk susceptibility genes, whole exome sequencing will be used to mutation screen two subjects each from a series of multi-generation colon cancer pedigrees. Role: Co-Principal Investigator U01 CA89600 (PTE PI: Thibodeau; Site PI: Cannon-Albright) 9/1/12- 8/31/17 0.6 calendar National Institutes of Health $1,394,647 Title: Prostate cancer susceptibility ? the ICPCG Study (International Consortium on Prostate Cancer Genetics) Goals: The purpose of this project is to analyze genotypic data from regions of interest on high-risk pedigrees. Role: Principal Investigator, University of Utah subaward 1R01CA161780-01A1 (Schiffman) 4/1/12-3/31/17 0.36 calendar National Institutes of Health $2,026,843 Title: Genetic Risk Factors of Ewings Sarcoma Goals: The purpose of this project is to determine the association between the length of EWS-FL11 fusion protein binding sites (MSRS) and risk of ES, to determine the frequency and commonality of Caucasian ancestral markers in cases of ES self-identified as non-Caucasian, as well as to determine the association between genomic variants associated with hernia development and risk of ES. Role: Co-Investigator SPLB-001-14S (Cannon-Albright) 7/1/14-6/30/17 Effort: 5/8 Department of Veterans Affairs $1,201,059 Title: Creation and Analysis of a National VA Genealogy/Medical Phenotype Resource Goals: The purpose of this project is to develop a complete U.S. genealogy linked to nationwide VHA data which could someday provide the basis for individual relative risk estimations, segregation studies, disease association studies, pharmacogenomic studies, gene expression. Role: Principal Investigator W81XWH-14-PCRP-IDA (Cannon-Albright) 9/21/15-9/20/17 1.2 calendar Department of Defense $553,483 Title: Identification of Prostate Cancer Predisposition Genes on the Y Chromosome Goals: We hypothesize the existence of Y chromosome genes related to increased risk, and here propose an innovative study to identify the responsible Y chromosome genes or variants. Role: Principal Investigator R01 DE023414 (Hashibe/Tavtigian) 7/1/14-6/30/19 0.6 calendar National Institutes of Health $2,659,573 Title: Exome sequencing for head and neck cancer susceptibility genes Goals: The major goals of the project are to exome sequence 200 familial head and neck cancer cases, apply case-control mutation screening to the candidate predisposition genes identified in 2,000 cases and 2,000 controls, and assess whether the genetic risks differ by subsite and epidemiologic risk groups. Role: Co-Investigator 1R01CA195614 (Huff/Cannon-Albright) 4/1/15-3/31/20 0.96 calendar National Institutes of Health $3,645,966 Title: High throughput sequencing to identify novel melanoma susceptibility genes Goals: To identify candidate genes and novel melanoma-gene associations and test for somatic-germline interaction by targeted sequencing of tumor samples Role: Co-Principal Investigator

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Research Grant (Cannon-Albright) 8/1/14-12/9/16 0.6 calendar Intermountain Research and Medical Foundation $60,000 Title: Familiality in Brain Tumors; a genotyping study of pedigrees of brain tumor patients with increased relativity, from the Utah Population Data Base (UPDB) and Intermountain BioRepository (IBR) Goal: To identify genes/variants associated with predisposition to development of brain tumors using high-risk pedigree resources uniquely available in Utah. Role: Principal Investigator

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. BRCA1 patent BRCA2 patent p16 patent

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (S.B.G., K.P.F., M.B.B., S.M.P.) and Division of Genetic Epidemiology, Department of Internal Medicine (D.A., J.M.F., K.K.T., L.C.-A.), University of Utah, School of Medicine, Salt Lake City; College of Behavioral and Social Science (H.M.), University of Utah, Salt Lake City; and George E. Wahlen Department of Veterans Affairs Medical Center (L.C.-A.), Salt Lake City, UT.
  1. Correspondence to Dr. Cannon-Albright: lisa.albright{at}utah.edu
View Full Text

Article usage

Article usage: May 2016 to December 2022

AbstractFullPdfSource
May 2016927034Highwire
Jun 201619706Highwire
Jul 201613731529Highwire
Aug 2016315612Highwire
Sep 201615036Highwire
Oct 20169211Highwire
Nov 20166614Highwire
Dec 201658310Highwire
Jan 20177252Highwire
Feb 20175246Highwire
Mar 20174401Highwire
Apr 20176032Highwire
May 20174301Highwire
Jun 20173087Highwire
Jul 20171910Highwire
Jul 2017242pmc
Aug 20171602Highwire
Aug 2017022pmc
Sep 20172502Highwire
Sep 2017666pmc
Oct 20172100Highwire
Oct 20173910pmc
Nov 2017800Highwire
Nov 201751413pmc
Dec 20171322Highwire
Jan 20181701Highwire
Feb 20181710Highwire
Mar 2018900Highwire
Apr 20181011Highwire
Apr 201831521pmc
May 20181401Highwire
Jun 20181500Highwire
Jun 201822223pmc
Jul 20181400Highwire
Aug 2018812Highwire
Aug 201862726pmc
Sep 20181500Highwire
Oct 20182103Highwire
Nov 20181422Highwire
Dec 20182701Highwire
Jan 20191602Highwire
Feb 20192701Highwire
Mar 20191053Highwire
Apr 20191625Highwire
May 20192900Highwire
Jun 20191301Highwire
Jul 20191653Highwire
Aug 20191313Highwire
Sep 2019800Highwire
Oct 20196503Highwire
Nov 20194214Highwire
Dec 20191800Highwire
Jan 20201410Highwire
Feb 20201301Highwire
Mar 20201000Highwire
Apr 20201300Highwire
May 20201111Highwire
Jun 20202800Highwire
Jul 20201600Highwire
Aug 20203101Highwire
Sep 20203221Highwire
Oct 20203011Highwire
Nov 20203610Highwire
Dec 20202200Highwire
Jan 20213400Highwire
Feb 20212610Highwire
Mar 20212000Highwire
Apr 20212101Highwire
May 20211600Highwire
Jun 20211100Highwire
Jul 20211800Highwire
Aug 20212311Highwire
Sep 20212300Highwire
Oct 20211100Highwire
Nov 20212000Highwire
Dec 20212300Highwire
Jan 20222013Highwire
Feb 20222801Highwire
Mar 20221400Highwire
Apr 20222011Highwire
May 20221411Highwire
Jun 20223712Highwire
Jul 20223501Highwire
Aug 20222821Highwire
Sep 20221600Highwire
Oct 20223901Highwire
Nov 20222800Highwire
Dec 20221200Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me